Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
88
resultados
Última actualización
14/07/2026 [07:54:00]
Resultados 50 a 75 de 88
Resumen de: US20260152531A1
0000 Provided herein is a synthetic polypeptide derived from High Mobility Group Box 1 (HMGB 1) host protein that can both disrupt bacterial biofilms and prevent Neutrophil Extracellular Trap (NET) formation. Also provided herein are methods to disrupt aberrant or excessive NET formation that are particularly well-suited to treat high-risk populations such as those infected with SARS CoV-2, sepsis, autoimmune diseases e.g., systemic lupus erythematosus, rheumatoid arthritis, Type I diabetes mellitus, small vessel vasculitis, autoinflammatory diseases e.g., gout, inflammatory bowel disease, and metabolic diseases e.g., Type 2 diabetes and obesity.
Resumen de: US20260151415A1
0000 Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.
Resumen de: WO2026112937A1
Relate to an isolated vNAR single domain antibody that specifically binds to SARS-CoV-2 nucleocapsid protein, and a process for preparing the same.This isolated vNAR single domain antibody are also included.
Resumen de: US20260151476A1
0000 Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-COV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.
Resumen de: EP4751641A2
Disclosed are methods and devices for analyzing non-volatile organics in exhaled breath and other aerosols using various diagnostic tools that enable rapid, low cost point of care assays for several diseases including respiratory tract diseases such as COVID-19. The disclosed methods and systems selectively capture non-volatile organics in exhaled breath and other aerosols in a packed bed column. The non-volatile organics are eluted and samples are analysis using diagnostic devices including MALDI-TOFMS. The disclosed systems and methods provide for a diagnostic test result in less than about 20 minutes and provides for autonomous operation with minimal human intervention.
Resumen de: EP4751733A2
The present invention relates to method of producing a lipidated protein, a pharmaceutical composition comprising the protein of any of SEQ ID NOs: 1, 2, and/or 3 and/or the lipidated form of a protein comprising the protein of SEQ ID NO: 7 (C-TAB.GS) and/or SEQ ID NO: 8 (C-TAB.G5.1), especially the protein of SEQ ID NO: 12 (Lip-C-TAB.G5.1), and/or a lipidated form of a protein comprising the protein of SEQ ID NO: 15 (Spike protein of SARS-CoV-2) and/or a lipidated form of a protein comprising the any of the proteins of SEQ ID NOs: 16-22 (hMPV F protein), and the pharmaceutical composition for use as a medicament, particularly a vaccine and/or for use in a method for eliciting an immune response in a human against Lyme disease, a disease caused by Clostridium difficile or hMPV and/or of SARS-CoV-2 (COVID-19).
Resumen de: WO2025022303A1
The present invention relates to monoclonal antibodies or antigen-binding portion thereof that have a potent neutralizing activity against Coronavirus, in particular against at least one virus selected from SARS-CoV-2, SARS-CoV-1 and variants thereof. The invention relates also to the use of such monoclonal antibodies or antigen-binding portion thereof in therapy, prophylaxis, and diagnosis of Coronavirus, in particular SARS-CoV-2 and/or SARS-CoV-1 dependent diseases.
Resumen de: US12643063B1
0000 The present development is a nanofilter, i.e. a filter material that comprises inorganic nanowires impregnated into a non-woven polymer or cloth fabric material. The nanofilter comprises a fabric infiltrated with a nanowire powder slurry selected from anatase titania (TiO<2>), zinc oxide (ZnO), silica, tin oxide, alumina (Al<2>O<3>), or combinations thereof. Exemplary fabrics include a non-woven polymer and a cotton fabric cloth. The nanowire powder slurry effectively produces a coating on the fabric. Optionally, the nanowires may be functionalized using nanoparticles and/or disinfecting salt particles. The infiltrated nanowires form a porous network with sub-micron scale openings and provide filtration of any airborne particles, liquid droplets and viruses including COVID 19. The nanofilter may be used in a variety of applications, such as a nanofilter respirator as described herein.
Resumen de: KR20260080874A
본 발명은 코로나19에 따른 제주 입도수요 충격 데이터 보정 방안을 기반으로한 모델 학습을 위한 충격 데이터 보정 방안 연구 에 관한 것으로서 제주 관광 수요 예측 정확도를 높이고 외부 충격에 대한 대응 능력을 강화하는 데 기여한다. 또한 체계적 표준화가 미흡한 현 관광 산업의 데이터 분석 환경에 새로운 방법론을 제시함으로써, 데이터 기반의 과학적 분석과 의사 결정이 가능한 체계를 구축하는 데 기여할 것으로 기대된다.하도록 함으로써 기존의 제주도 관광 산업은 지역 GRDP의 21%를 차지하며 2023년 관광객 1,400만 명을 기록했다. 그러나 관광 수요예측은 계절, 경제, 사회적 요인의 영향 및 복잡한 비선형 관계를 가지고 있어 선형 중심의 전통적 통계모형으로는 외생 요인들의 영향을 효과적으로 반영하기 어렵다. 특히 코로나19와 같은 충격 데이터를 단순 제거하면 중요한 정보가 손실될 수 있다. 따라서 본 연구는 통계모형과 기계학습을 결합해 충격 데이터의 특성을 반영한 새로운 관광 수요 예측 방법을 제시한다. 문제점을 해소 하도록 한 것이다.즉 본 발명은, 기존 관광 산업의 수요예측은 기본적 통계모델(Arima)로만 진행됨 에 있어서 통계모형과 기계학습을 결합해 충격 데이터의 특성을 반영한 새로운 관광 수�
Resumen de: MX2026005926A
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
Resumen de: WO2025090605A1
The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
Resumen de: MX2026005520A
Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies.
Resumen de: KR20260078113A
본 발명은 오시머티닙(osimertinib)을 유효성분으로 포함하는 SARS-CoV-2 바이러스 또는 SARS-CoV-2 변이체 바이러스에 대한 항바이러스용 조성물에 관한 것으로서, 세포 생존율 감소와 무관하게 hACE2를 발현하는 세포 및 3D 스페로이드에 처리 시 야생형뿐만 아니라 변이체 바이러스의 감염이 감소되는 효과를 가지므로, ARS-CoV 바이러스 또는 SARS-CoV-2 변이체 바이러스의 감염 예방, 개선 및 치료에 사용할 수 있을 것으로 기대된다.
Resumen de: CA3126560A1
A method of treating or preventing a Coronaviridae infection in a subject comprising administrating a therapeutically effective amount of a compound of Formula I or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the Coronaviridae comprises at least one selected from 2019-nCov virus, HCov 229E virus, SARS virus, MERS virus,
Resumen de: WO2026108766A1
Provided herein are live attenuated viruses for protection against respiratory syncytial virus (RSV) and/or coronavirus Sars-CoV-2. The live attenuated chimeric virus strains utilize a master backbone based on a live attenuated influenza virus (LAIV), which includes a deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1). These chimeric strains are engineered to express one or more antigens of RSV alone or in combination with Sars-CoV-2. The chimeric virus strain can protect a subject in need thereof against a challenge from any of RSV, Sars-CoV-2, influenza, or a combination thereof. This viral vector system offers an important strategy for developing highly attenuated and immunogenic live attenuated vaccines with the capacity to induce protective immunity against the three respiratory infections.
Resumen de: AU2024395949A1
The present disclosure relates to methods of diseases and/or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.
Resumen de: US20260146062A1
0000 Compositions and methods are provided for inhibiting the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Resumen de: US20260146077A1
0000 Disclosed are monoclonal antibodies, antigen binding fragments, and bi-specific antibodies that specifically bind SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies. In some embodiments, the SARS-CoV-2 is the BA.4 or BA.5 variant.
Resumen de: WO2026112441A1
The present disclosure relates to compositions and methods, including prodrugs of (S)-3-(3-(((3,4- dimethoxybicyclo4.2.0octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2H- benzodazepin-2-one that find use in the treatment of diseases and disorders, such as therapies for cardiovascular disease, including cardiac arrhythmias, including, without limitations, sinus tach (e.g. inappropriate sinus tachycardia (IST)), postural orthostatic tachycardia syndrome (POTS), coronavirus (COVID-19) (e.g. long COVID) and COVID-associated cardiovascular abnormalities, supraventricular tachycardia (SVT), tachycardia (e.g. rapid heart rate, atrial tachycardia), heart failure (e.g. congestive heart failure (CHF), systolic heart failure, pediatric heart failure, chronic heart failure), myocardial ischaemia, angina (e.g. angina pectoris), myocardial infarct, rhythm disturbances (e.g. supraventricular rhythm disturbances), chest pain, cardiomyopathy, coronary artery disease, and left ventricular dysfunction (LVD).
Resumen de: US20260144861A1
0000 This disclosure relates to the field of RNA to prevent or treat multiple infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection, and/or RSV infection and inducing effective coronavirus, influenza virus, and/or RSV antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject (i) a bivalent RNA vaccine encoding peptides or proteins comprising epitopes of SARS-CoV-2 spike proteins (S proteins) and (ii) a tetravalent RNA vaccine encoding peptides or proteins comprising epitopes of hemagglutinin (HA), for inducing an immune response against coronavirus S proteins, in particular S proteins of SARS-CoV-2, and influenza proteins, in particular HA proteins of type A and type B influenza viruses, in the subject.
Resumen de: WO2026110758A1
Problem To provide a VHH which specifically binds to receptor binding domains of spike proteins of various types of variants of SARS-CoV2. Solution A VHH having any one or more of the characteristic properties mentioned below can recognize various types of variants of SARS-CoV2. (a) The VHH binds to Wuhan-Hu-1, delta variant, or micron variant of SARS-CoV2. (b) CDR1, CDR2, and CDR3 include the amino acid sequences represented by SEQ ID NOs: 1, 2, and 3, respectively; and/or (c) the VHH recognizes the amino acid sequence represented by SEQ ID NO: 4 and/or the amino acid sequence represented by SEQ ID NO: 5. This fusion protein which is obtained by fusing the VHH with ACE2 or an Fc form thereof enhances the SARS-CoV2 neutralizing capability and can be used in a pharmaceutical composition for treating or preventing COVID-19.
Resumen de: ZA202301746B
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease 2019 (COVID-19), has emerged as an ongoing global pandemic. Presently, there are no clinically approved vaccines nor drugs for COVID-19. Hence, there is an urgent need to accelerate the development of effective antivirals. One or more members of the 8-Hydroxyquinoline and Benzylamine structural classes inhibited SARS-CoV-2 infection induced cytopathic effect in vitro, inhibited the exopeptidase activity of angiotensin converting enzyme 2 (ACE2), and disrupted the binding between ACE2 and the Spike protein of SARS-CoV-2. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: MA70469B1
La présente invention concerne des anticorps et des fragments de liaison à l'antigène de ceux-ci qui se lient spécifiquement à la protéine de spicule du SARS-CoV-2 et des procédés de fabrication et d'utilisation de ceux-ci. Les anticorps peuvent être utilisés, par exemple, dans la prophylaxie, la prophylaxie post-exposition, ou le traitement d'une infection par le SARS-CoV-2. Les anticorps peuvent également être utilisés pour détecter le SARS-CoV-2, notamment une infection chez un sujet.
Resumen de: US12636282B1
Coronavirus disease of 2019 (COVID-19) is an acute viral infection that can trigger complicated immune system responses depending on the host. This disclosure discloses immunotherapy methods combining immunomodulators and antivirals to prevent and to reduce the severity of a COVID-19 infection. Successful treatment of COVID-19 requires prevention, early recognition and detection, the ruling out of co-infections, serial laboratory monitoring, and clinical monitoring for worsening and timely treatments during the acute phase and post-viral syndrome. Using this disclosure as preventive, management and therapeutic options for COVID-19, infected patients can be more resilient to viral challenges, recovering faster with less organ damages and adverse residual effects.
Nº publicación: US20260139035A1 21/05/2026
Solicitante:
NATIONAL UNIV CORPORATION KUMAMOTO UNIV [JP]
THE UNIV OF TOKYO [JP]
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
The University of Tokyo
Resumen de: US20260139035A1
It is an object of the present invention to provide an antibody against coronavirus (SARS-CoV-2) variants. It is also an object of the present invention to provide a pharmaceutical composition against coronavirus infection using the antibody. The present invention provides an antibody or antigen-binding fragment thereof that binds to the spike protein of the coronavirus and has the ability to neutralize coronaviruses, including the Omicron variant, and a pharmaceutical composition for the prevention or treatment of coronavirus infection, which contains the antibody or an antigen-binding fragment thereof.
BOPI
Sede Electrónica
